Friday, 16 October 2026European Markets

TELENET GROUP Stock Bullish Momentum With A 9.67% Jump On Thursday

Loading stream...

(VIANEWS) - The Market ended the session with TELENET GROUP (TNET.BR) jumping 9.67% to €15.20 on Thursday, after two consecutive sessions in a row of losses. BEL 20 jumped 0.62% to €3,652.55, after five successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

TELENET GROUP's last close was €14.33, 55.88% under its 52-week high of €32.48.

About TELENET GROUP

Telenet Group Holding NV provides basic and enhanced video services to residential and business customers in Belgium and Luxembourg. The company offers high definition, pay television, and video-on-demand services; broadband Internet services; fixed-line and mobile telephony services; voice, data, and Internet services; interconnection services; and value-added services, such as hosting, managed security, and cloud services. It also sells mobile handsets and set-top boxes; and provides advertising and production services, as well as product activation and installation services. The company serves small and medium enterprises, larger corporations, public, healthcare and educational institutions, and carrier customers that include international voice, data, and internet service providers. Telenet Group Holding NV was founded in 1994 and is headquartered in Mechelen, Belgium. Telenet Group Holding NV is a subsidiary of Liberty Global plc.

Earnings Per Share

As for profitability, TELENET GROUP has a trailing twelve months EPS of €2.73.

PE Ratio

TELENET GROUP has a trailing twelve months price to earnings ratio of 5.56. Meaning, the purchaser of the share is investing €5.56 for every euro of annual earnings.

More news about TELENET GROUP (TNET.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com